SEC Filing Summary: Athira Pharma, Inc. (ATHA)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on October 3, 2025, reporting events as of October 2, 2025. The Company is a Delaware corporation listed on The Nasdaq Capital Market under the symbol "ATHA." The filing addresses the status of the Company's compliance with Nasdaq listing requirements.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary event reported is the resolution of a listing deficiency. On October 16, 2024, the Company received notice that its common stock closing bid price had fallen below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Requirement. On October 2, 2025, the Company received notice from Nasdaq confirming that the closing bid price had been $1.00 per share or greater for ten consecutive business days. Consequently, the Company has regained compliance, and the matter is closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk addressed was the potential delisting due to low stock price, which has been resolved as of the report date. No other contingencies or unusual items are disclosed in this document.
Investor Verification Checklist
- Verify the current trading price of ATHA to ensure continued compliance with the $1.00 minimum bid requirement.
- Confirm the Company's status on the Nasdaq Capital Market via the exchange's official website.
- Review the Company's most recent 10-Q or 10-K for financial performance data, as this 8-K contains no financial figures.
- Monitor future communications for any new listing deficiency notices.